Replies to post #1879 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

…are you surprised that ENTA went up after that earnings revenue miss?

I’m not surprised at today’s positive price action because the stock sold off quite a bit in anticipation of the bad quarter (#msg-155360453).

Does the recent data mean EDP-305 is dead and ENTA's focus for NASH will be on EDP-297?

Unfortunately (from my viewpoint), it doesn’t mean that. ENTA is still planning to conduct a phase-2b trial of EDP-305 in NASH concurrently with running a phase-1 trial of EDP-297.

About half of yesterday’s CC was devoted to ENTA’s COVID-19 program, even though ENTA’s commitment of resources to this program is minimal (one virologist and one chemist). Given ENTA’s proven expertise in antiviral drug discovery, they may be able to find a DAA regimen that is safe and effective in early-stage COVID-19 disease; however, this won’t happen soon enough to affect the near-term path of the pandemic.